Edition:
India

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

7.64USD
23 Oct 2020
Change (% chg)

$0.05 (+0.66%)
Prev Close
$7.59
Open
$7.66
Day's High
$7.70
Day's Low
$7.27
Volume
79,434
Avg. Vol
257,888
52-wk High
$8.68
52-wk Low
$1.49

Latest Key Developments (Source: Significant Developments)

Aldeyra Therapeutics Q2 Loss Per Share $0.25
Thursday, 6 Aug 2020 

Aug 6 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES SECOND-QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.25.Q2 EARNINGS PER SHARE ESTIMATE $-0.34 -- REFINITIV IBES DATA.ASSESSMENT OF TEAR RASP LEVELS IN DRY EYE DISEASE PATIENTS EXPECTED TO BEGIN IN Q4.NEW DRUG APPLICATION (NDA) SUBMISSION FOR REPROXALAP IN DRY EYE DISEASE EXPECTED BY END OF 2021.CURRENT CASH EXPECTED TO SUPPORT OPERATIONS THROUGH 2022.ALDEYRA THERAPEUTICS - AS OF JUNE 30, CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $66.2 MILLION.  Full Article

Aldeyra Therapeutics Announces New Drug Application Development Plans For Dry Eye Disease
Tuesday, 7 Jul 2020 

July 7 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES NEW DRUG APPLICATION (NDA) DEVELOPMENT PLANS FOR DRY EYE DISEASE.ALDEYRA THERAPEUTICS INC - TOP-LINE RESULTS FROM FIRST OF TWO PLANNED CLINICAL TRIALS BASED ON TEAR RASP LEVELS EXPECTED BY END OF 2020.ALDEYRA THERAPEUTICS INC - NEW DRUG APPLICATION SUBMISSION FOR REPROXALAP IN DRY EYE DISEASE EXPECTED BY END OF 2021.ALDEYRA THERAPEUTICS INC - BASED ON CURRENT OPERATING PLANS, CURRENT CASH EXPECTED TO SUPPORT OPERATIONS INTO 2022.  Full Article

Aldeyra Therapeutics To Test ADX-1612 Against COVID-19
Wednesday, 20 May 2020 

May 20 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS TO ADVANCE ADX-1612, AN INVESTIGATIONAL NEW HSP90 INHIBITOR WITH POTENTIAL NANOMOLAR POTENCY AGAINST SARS-COV-2, TO CLINICAL TESTING FOR COVID-19; ADX-629 ACCEPTED FOR BARDA CORONAWATCH MEETING.ALDEYRA THERAPEUTICS INC - IND SUBMISSION FOR ADX-629 EXPECTED IN JUNE 2020.ALDEYRA THERAPEUTICS INC - PENDING FDA FEEDBACK, IND SUBMISSION FOR ADX-1612 EXPECTED IN Q3 2020.ALDEYRA THERAPEUTICS INC - ADX-1612 DEMONSTRATES NANOMOLAR SARS-COV-2 ANTIVIRAL POTENCY IN VITRO.ALDEYRA THERAPEUTICS INC - ANNOUNCED PLANNED ADVANCEMENT OF INVESTIGATIONAL NEW HSP90 INHIBITOR ADX-1612 TO CLINICAL TESTING FOR COVID-19.  Full Article

Aldeyra Therapeutics Q1 Loss Per Share $0.34
Thursday, 7 May 2020 

May 7 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS AND ANNOUNCES NEW CLINICAL PROGRAMS.Q1 LOSS PER SHARE $0.34.Q1 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.ADX-629 EXPECTED TO BEGIN PHASE 2 CLINICAL TRIALS IN COVID-19 RESPIRATORY COMPROMISE, ATOPIC ASTHMA, AND PSORIASIS IN 2020.TYPE C MEETING SCHEDULED WITH FDA TO DISCUSS REMAINING NDA REQUIREMENTS FOR REPROXALAP IN DRY EYE DISEASE.RESULTS FROM PHASE 3 INVIGORATE TRIAL OF REPROXALAP IN ALLERGIC CONJUNCTIVITIS EXPECTED IN FIRST HALF OF 2021.CASH RUNWAY EXTENDED INTO 2022.  Full Article

Aldeyra To Screen Clinical-Stage Compounds For Activity In COVID-19 Infection
Tuesday, 24 Mar 2020 

March 24 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA TO SCREEN CLINICAL-STAGE COMPOUNDS FOR ACTIVITY IN COVID-19 INFECTION.ALDEYRA - TO BEGIN SCREENING LIBRARY OF NOVEL RASP INHIBITORS, FOR POTENTIAL ANTI-INFLAMMATORY & ANTIVIRAL ACTIVITY IN TREATMENT OF COVID-19 INFECTION.ALDEYRA THERAPEUTICS INC - SUBMITTED A PROPOSAL TO BARDA FOR DEVELOPMENT OF ADX-629 FOR TREATMENT OF COVID-19 INFECTION.ALDEYRA THERAPEUTICS INC - ALSO SEEKING HEALTHCARE INDUSTRY PARTNERS THAT MAY BE INTERESTED IN TESTING ADX-629.  Full Article

Aldeyra Therapeutics Provides Updates On Anticipated Clinical Milestones
Thursday, 12 Mar 2020 

March 12 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS REPORTS FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES UPDATES ON ANTICIPATED CLINICAL MILESTONES.ALDEYRA THERAPEUTICS - STRATEGIC PRIORITIZATION OF LATE-STAGE OCULAR PIPELINE EXPECTED TO EXTEND CASH RUNWAY THROUGH END OF 2021.ALDEYRA - TO PLACE ON HOLD CLINICAL DEVELOPMENT OF TOPICAL DERMAL REPROXALAP FOR TREATMENT OF ICHTHYOSIS ASSOCIATED WITH SJOGREN-LARSSON SYNDROME.ALDEYRA THERAPEUTICS INC - TO PLACE ON HOLD ITS CLINICAL DEVELOPMENT OF ADX-1612 FOR TREATMENT OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER..  Full Article

Aldeyra Therapeutics To Provide Update On Late-Stage Clinical Development Pipeline At 2020 Research & Development Day
Monday, 24 Feb 2020 

Feb 24 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS TO PROVIDE UPDATE ON LATE-STAGE CLINICAL DEVELOPMENT PIPELINE AT 2020 RESEARCH & DEVELOPMENT DAY.ALDEYRA THERAPEUTICS INC - PRIMARY ENDPOINT OF SYMPTOM CONTROL ACHIEVED IN PHASE 2 DRY EYE DISEASE FORMULATION CLINICAL TRIAL.ALDEYRA - STATISTICALLY SIGNIFICANT COMBINED DATA ACROSS MULTIPLE DRY EYE DISEASE TRIALS SUGGESTS POTENTIAL EARLY, POTENT ACTIVITY IN SIGNS, SYMPTOMS.  Full Article

Aldeyra Therapeutics Announces Positive Top-Line Results From Part 1 Of Adaptive Phase 3 Renew Trial In Dry Eye Disease
Tuesday, 3 Dec 2019 

Dec 3 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PART 1 OF ADAPTIVE PHASE 3 RENEW TRIAL IN DRY EYE DISEASE.ALDEYRA THERAPEUTICS INC - RENEW PART 2 EXPECTED TO INITIATE IN FIRST HALF OF 2020.ALDEYRA - REPROXALAP STATISTICALLY SUPERIOR TO VEHICLE IN RENEW CO-PRIMARY ENDPOINT OF OCULAR DRYNESS SCORE IN INDUCTION-MAINTENANCE REGIMEN.ALDEYRA THERAPEUTICS INC - PRIMARY OBJECTIVE OF RENEW PART 1 ACHIEVED.ALDEYRA THERAPEUTICS- RELATIVE TO VEHICLE, INDUCTION-MAINTENANCE DOSING REGIMEN DEMONSTRATED STATISTICALLY SIGNIFICANT ACTIVITY IN RENEW TRIAL.  Full Article

Aldeyra Therapeutics Q3 Loss Per Share $0.69
Thursday, 7 Nov 2019 

Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS REPORTS THIRD-QUARTER 2019 FINANCIAL RESULTS AND PROVIDES UPDATES ON ANTICIPATED CLINICAL MILESTONES.Q3 LOSS PER SHARE $0.69.Q3 EARNINGS PER SHARE ESTIMATE $-0.55 -- REFINITIV IBES DATA.ADAPTIVE GUARD PHASE 3 CLINICAL TRIAL OF ADX-2191 IN PROLIFERATIVE VITREORETINOPATHY TO INITIATE IN Q4 2019.PART I OF ADAPTIVE RENEW PHASE 3 CLINICAL TRIAL IN DRY EYE DISEASE ON TRACK FOR COMPLETION IN Q4 2019.INITIATION OF INVIGORATE PHASE 3 CLINICAL TRIAL OF REPROXALAP IN ALLERGIC CONJUNCTIVITIS PLANNED FOR FIRST HALF 2020.PHASE 1 CLINICAL TRIAL OF NOVEL, ORALLY ADMINISTERED RASP INHIBITOR ADX-629 INITIATED."EXPECT OUR CLINICAL MOMENTUM TO ACCELERATE AS WE MOVE THROUGH Q4 OF THIS YEAR AND INTO 2020".AS OF SEPTEMBER 30, 2019, CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $76.2 MILLION.  Full Article

Aldeyra Therapeutics Releases Expanded Results From Allergen Chamber Trial And Announces Plans To Initiate Allergic Conjunctivitis Phase 3 Trial
Thursday, 31 Oct 2019 

Oct 31 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS RELEASES EXPANDED RESULTS FROM ALLERGEN CHAMBER TRIAL AND ANNOUNCES PLANS TO INITIATE THE PHASE 3 INVIGORATE TRIAL IN PATIENTS WITH ALLERGIC CONJUNCTIVITIS.ALDEYRA THERAPEUTICS RELEASES EXPANDED RESULTS FROM ALLERGEN CHAMBER TRIAL AND ANNOUNCES PLANS TO INITIATE THE PHASE 3 INVIGORATE TRIAL IN PATIENTS WITH ALLERGIC CONJUNCTIVITIS.ALDEYRA THERAPEUTICS INC - AGREEMENT REACHED WITH U.S. FDA ON DESIGN OF PHASE 3 INVIGORATE TRIAL, EXPECTED TO INITIATE IN FIRST HALF OF 2020.ALDEYRA THERAPEUTICS INC - HIGHLY STATISTICALLY SIGNIFICANT ACTIVITY RELATIVE TO VEHICLE ACROSS EVERY ASSESSED SYMPTOM AND SIGN OBSERVED.ALDEYRA THERAPEUTICS INC - ALL TIME POINTS TO BE PRE-SPECIFIED IN INVIGORATE TRIAL WERE STATISTICALLY SIGNIFICANT.  Full Article

BRIEF-Aldeyra Therapeutics Announces New Drug Application Development Plans For Dry Eye Disease

* ALDEYRA THERAPEUTICS ANNOUNCES NEW DRUG APPLICATION (NDA) DEVELOPMENT PLANS FOR DRY EYE DISEASE